synthetic peptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
The velocity of the charged particle after acceleration will not change since it moves in a field-free time-of-flight tube. The velocity of the particle can be determined in a time-of-flight tube since the length of the path (d) of the flight of the ion is known and the time of the flight of the ion (t) can be measured using a transient digitizer or time to digital converter. Thus,
In 1842, John Gorrie created a system capable of refrigerating water to produce ice. Although it was a commercial failure, it inspired scientists and inventors around the world. France's Ferdinand Carre was one of the inspired and he created an ice producing system that was simpler and smaller than that of Gorrie. During the Civil War, cities such as New Orleans could no longer get ice from New England via the coastal ice trade. Carre's refrigeration system became the solution to New Orleans' ice problems and, by 1865, the city had three of Carre's machines. In 1867, in San Antonio, Texas, a French immigrant named Andrew Muhl built an ice-making machine to help service the expanding beef industry before moving it to Waco in 1871. In 1873, the patent for this machine was contracted by the Columbus Iron Works, a company acquired by the W.C. Bradley Co., which went on to produce the first commercial ice-makers in the United States. By the 1870s, breweries had become the largest users of harvested ice. Though the ice-harvesting industry had grown immensely by the turn of the 20th century, pollution and sewage had begun to creep into natural ice, making it a problem in the metropolitan suburbs. Eventually, breweries began to complain of tainted ice. Public concern for the purity of water, from which ice was formed, began to increase in the early 1900s with the rise of germ theory. Numerous media outlets published articles connecting diseases such as typhoid fever with natural ice consumption. This caused ice harvesting to become illegal in certain areas of the country.
==== Available forms ==== Adderall is available as immediate-release (IR) tablets and extended-release (XR) capsules. Mydayis is available as an extended-release formulation. Adderall XR is approved to treat attention deficit hyperactivity disorder for up to 12 hours in individuals 6 years and older and uses a double-bead formulation. The capsule can be swallowed like a tablet, or it can be opened and the beads sprinkled over applesauce for comparable absorption. Upon ingestion, half of the beads provide immediate administration of medication, while the other half are enveloped in a coating that must dissolve, delaying absorption of its contents. It is designed to provide a therapeutic effect and plasma concentrations identical to taking two doses of Adderall IR four hours apart. Mydayis uses a longer-lasting triple-bead formulation and is approved to treat attention deficit hyperactivity disorder for up to 16 hours in individuals aged 13 years of age and older. In the United States, the immediate and extended-release formulations of Adderall are available as generic medications. Generic formulations of Mydayis became available in the US in October 2023.
The white shark's genome has remained relatively stable in its evolution. As a species, it does not behave as a unified metapopulation at the global scale. Instead, populations within the major ocean basins show distinct genetic lineages that diverged from each other at least thousands of years ago. A 2020 mitochondrial DNA (mDNA) (mother-inherited) study concluded that Mediterranean sharks show closer affinity with Australia/New Zealand and Northeastern Pacific sharks than with sharks from South Africa and the Northwestern Atlantic. The researchers suggested that, over 3 mya, sharks from the former region swam to South Africa and north in response to Pleistocene climatic cycles and ended up in the Mediterranean. A 2024 study cautioned that mDNA is "informative about the species' deep history but are of very limited use for estimating recent connectivity". Using nuclear DNA (both mother- and father-inherited), the study concluded that white shark populations can be divided into three major branches or clades: North Atlantic (represented by the US East Coast and Mediterranean), Indo-Pacific (represented by Australia, New Zealand and South Africa), and North Pacific (represented by California, Baja California, and East Asia). These diverged relatively recently, around 100,000–200,000 years ago, in response to lowered sea levels. A 2025 study affirmed the existence of these three clades but found that they diverged around 7,000 years ago following a decline in the global white shark population, which started 800,000 years ago.
=== Underwater work === Chainsaws are used for underwater cutting by professional divers. They are usually driven by hydraulic power supplied from the surface and operated by commercial divers using surface-supplied diving equipment. Underwater chainsaw cutting may also be used by public safety divers. Hydraulic chainsaws can be used to cut wood, concrete, brick and steel if the appropriate chain is used. Underwater cutting may be done in conditions of moving water and low visibility, which can increase risk, and appropriate safety precautions and suitable procedures are required for safety. Underwater wood structures may include bridge pilings, pier, and dock timbers. Chain saws generally include an interlocking safety trigger with hand guard.
Sources: en.wikipedia.org
On a pressure/temperature phase diagram (see figure), there are curves separating solid from vapor, vapor from liquid, and liquid from solid. These meet at a single point called the triple point, where all three phases can coexist. The triple point is at a temperature of 273.16 K (0.01 °C; 32.02 °F) and a pressure of 611.657 pascals (0.00604 atm; 0.0887 psi); it is the lowest pressure at which liquid water can exist. Until 2019, the triple point was used to define the Kelvin temperature scale. The water/vapor phase curve terminates at 647.096 K (373.946 °C; 705.103 °F) and 22.064 megapascals (3,200.1 psi; 217.75 atm). This is known as the critical point. At higher temperatures and pressures the liquid and vapor phases form a continuous phase called a supercritical fluid. It can be gradually compressed or expanded between gas-like and liquid-like densities; its properties (which are quite different from those of ambient water) are sensitive to density. For example, for suitable pressures and temperatures it can mix freely with nonpolar compounds, including most organic compounds. This makes it useful in a variety of applications including high-temperature electrochemistry and as an ecologically benign solvent or catalyst in chemical reactions involving organic compounds. In Earth's mantle, it acts as a solvent during mineral formation, dissolution and deposition.
South Africa did not compete at Olympic Games from 1964 to 1988, as a part of the sporting boycott of South Africa during the apartheid era. The South African National Olympic Committee (NOC) was expelled from the International Olympic Committee (IOC) in 1970. In 1991, as part of the transition to racial equality, South Africa was re-admitted to the IOC, and competed at the 1992 Summer Olympics held in Barcelona.
tissue In a multicellular organism, a contiguous aggregation of cells held together by a common extracellular matrix and specialized to perform a particular function. Some tissues are composed primarily of a single cell type; others are a heterogeneous mixture of many cell types. Tissues represent a level of multicellular organization between that of individual cells and that of organs, which may be composed of one or more distinct types of tissue.
== Further reading == Peters, U H (1992), "[Introduction of shock therapy and psychiatric emigration]", Fortschritte der Neurologie-Psychiatrie, vol. 60, no. 9 (published Sep 1992), pp. 356–365, doi:10.1055/s-2007-999155, PMID 1398417, S2CID 71208271 "Manfred J. Sakel", Journal of Clinical and Experimental Psychopathology, vol. 15, no. 3, p. 319, 1954, PMID 13221647 Fink, M (1984), "Meduna and the Origins of Convulsive Therapy", American Journal of Psychiatry, 141(9): 1034-1041 (This historical and biographical paper discusses the introduction of the shock treatment in psychiatry, the role of a theory of the biological antagonism between epilepsy and schizophrenia, and the contributions of Ladislas J. Meduna, Sakel, Ugo Cerletti, and Lucio Bini.) Doroshow, DB: Performing a Cure for Schizophrenia: Insulin Coma Therapy on the Wards. Journal of the History of Medicine and Allied Sciences, Advance Access published online on November 14, 2006 Jones, K. Insulin coma therapy in schizophrenia. J. Royal Soc. Med, 93: 147-149, 2000.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.